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Background: Fractional flow reserve (FFR) has been recognized as useful modality to assess functional significance of coronary stenosis. It is 
important to obtain maximal hyperemia for optimal FFR measurement. Although adenosine triphosphate (ATP) is generally used as hyperemic 
stimulus, we sometimes encounter adverse events like hypotension for FFR measurement. Nicorandil, an ATP sensitive potassium channel opener, is 
recognized as epicardial and resistance vessel dilators. Little is known whether nicorandil has a potential as hyperemic agent. Therefore, we evaluate 
the utility and the safety of intracoronary nicorandil infusion compared to intravenous ATP for FFR measurement in coronary artery disease (CAD) 
patients. 
methods: This study consisted of 102 CAD patients with 124 intermediate lesions (diameter stenosis >40% and <70% by visual assessment). All 
vessels underwent FFR measurements with both ATP and nicorandil stimulus. All patients first received intravenous ATP infusion (150 μg/kg/min) and 
measured FFR (ATP-FFR). After the recovery to baseline was verified, patients received intracoronary nicorandil infusion (2.0 mg) and measured FFR 
(Nico-FFR). We evaluated FFR, hemodynamic values, and periprocedural adverse events between both agents. 
results: A total of 68 left anterior descending, 25 left circumflex, and 31 right coronary arteries were evaluated. In all lesions, reference vessel 
diameter was 2.8±0.6 mm and diameter stenosis was 54.0±11.9%. A strong correlation was observed between Nico-FFR and ATP-FFR (r=0.9541, 
p<0.0001). The agreement between the 2 sets of measurements was also high, with a mean difference of 0.0005 and 2SD of 0.06. The mean 
aortic pressure drop during pharmacological stimulus was significantly larger in ATP compared with nicorandil (10.7±9.5 mmHg vs. 4.8±7.3 mmHg, 
p<0.001). During FFR measurement, transient AV block and the fluctuation of FFR were frequently observed in ATP compared with nicorandil (4.0% 
vs. 0%, p=0.024; 21.0% vs. 0%, p<0.001, respectively). 
conclusions: This study suggests intracoronary nicorandil infusion is associated with clinical utility and safety compared to ATP as a hyperemic 
agent for measurement of FFR.
